The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.
Jackisch C, Anastasiadou L, Aulmann S, Argyriadis A, Möbus V, Solbach C, Baier P, Giesecke D, Ackermann S, Schulmeyer E, Gabriel B, Mosch D, Buchen S, Krapfl E, Hurst U, Vescia M, Tesch H, Thill M.
Jackisch C, et al. Among authors: gabriel b.
Breast Cancer Res Treat. 2024 Sep;207(2):263-274. doi: 10.1007/s10549-024-07390-y. Epub 2024 Jun 14.
Breast Cancer Res Treat. 2024.
PMID: 38874685
Free PMC article.